<DOC>
	<DOC>NCT00722046</DOC>
	<brief_summary>Purpose of the study is to determine whether multiple dose administration of PF-04360365 is safe and well tolerated in patient with mild to moderate Alzheimer's disease.</brief_summary>
	<brief_title>Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Males or females of non childbearing potential, age &gt; or = 50 Diagnosis of probable Alzheimer's disease, consistent with criterial from both: National Institute of Neurological and Communicable Disease and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDSADRDA) Diagnostic and Statistical Manual of Mental Disorders (DSM IV) Minimental status exam score of 1626 inclusive RosenModified Hachinski Ischemia Score of &lt; or = 4 Diagnosis or history of other demential or neurodegenerative disorders Diagnosis or history of clinically significant cerebrovascular disease Specific findings on magnetic resonance imaging (MRI); cortical infarct, micro hemorrhage, multiple white matter lacunes, extensive white matter abnormalities History of autoimmune disorders History of allergic or anaphylactic reactions</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Alzheimer's disease</keyword>
	<keyword>antibody</keyword>
	<keyword>amyloid</keyword>
</DOC>